Active and Pending Support Example

MOORE, Edgar Allen

**ACTIVE**
(Moore) American Lung Association
07/01/2009 – 06/30/2011 4.08 calendar
$140,000
Sythetic heparins
In this project, we will construct synthetic heparins with functional "domains" (AT and thrombin binding) using insights gained from Aim1 to reduce PF4 binding. In conducting these studies, we hope to generate preliminary data and gain insights into the design of a synthetic heparin compound with improved safety and efficacy.

R01 HL012345 (Moore)
04/01/2006 – 03/31/2012 6.27 calendar
NIH $218,475
Antibody
To investigate the hypothesis that HIT arises from a breach in self-tolerance brought about by exposure of antigenic multivalent PF4/heparin complexes and platelet CD154 that enable autoreactive T cells to stimulate antibody production.

(Moore) Blood Center of Miami
12/06/2010 – 11/30/2015 0.60 calendar
$6,682
Transfusion Medicine, Project 3
In this project, we will use the mouse models in combination with several other genetically-modified mouse strains to study how B cells regulate the immune pathogenesis of HIT, and determine whether manipulation of the PLCg2/PKC/Bcl10/TAK1 pathway to control B cell function can prevent HIT.

Duke Clinical Research Institute
06/17/2009 – 04/30/2013 0.12 calendar
BRIDGE Study $90,000
To compare the efficacy of bridging therapeutic-dose bleeding in patients who require temporary interruption of warfarin. Method of administration is by subcutaneous injection.

**PENDING:**

N/A (Moore)
04/01/2011 – 03/31/2018 2.40 calendar
UNC Chapel Hill $100,000
Side Effects
In this project, we will examine the efficacy and safety of synthetic heparin compounds in vivo using animal models. In pursuing the goals of this application, we hope to synthesize heparin compounds with broad therapeutic utility for a variety of indications, but a markedly reduced immunogenicity and risk for HIT.

N/A (Moore)
12/01/2011 – 11/30/2016 4.44 calendar
Children's Hospital of Philadelphia $205,000
Pathogenesis
This Project focuses on the immune pathogenesis of HIT, specifically, what triggers PF4/heparin antibody production in vivo. To gain insights into the cellular basis of the PF4/ heparin immune response, Dr. Moore will employ a novel murine immunization model that she developed.
Dysregulation
These proposed studies address why a life-threatening allergic response occurs to heparin, a commonly used blood thinner. Our studies will address the cellular triggers for this allergy. With an improved understanding of this allergic response, we hope to develop strategies for preventing this allergic reaction.

Heparins
This proposal is a collaborative effort of Dr. Gin group (University of North Carolina) and Dr. Moore group (Duke University) with a goal to reduce the side effect of heparin drugs.

OVERLAP
None, the ALA project will end before the pending project’s start date of 7/1/11.
Aggregated Effort Active Only Example

Kate Chopin, PhD

ACTIVE SUPPORT

WFUHS (Chopin) 9/29/09-8/31/11 3.16 calendar
Wake Forest University $171,649

Chemoprevention

In the proposed research, we will compare the cost and effectiveness of chemoprevention verse no chemoprevention for prostate cancer in three populations: all men; men with a positive family history of prostate cancer; and men at a high risk based on the prediction model.

5R01-NR022222-06 (Chopin) 9/29/09-7/31/12 4.58 calendar
NIH $267,695

Patient Management

The objective of the proposed project, TEAM-HF: Tools for Economic Analysis of Patient Management Interventions in Heart Failure, is to develop tools to facilitate the conduct of high-quality economic evaluations of health care interventions in heart failure, particularly those that involve patient-focused educational or behavioral modification elements.

5R01-HS032456-08 (Pare) 09/30/09 – 07/31/13 2.10 calendar
AHRQ $290,004

Patient Preference

The goal of this project is to develop a palliative care benefit for the Medicare program that is based on the care preferences of selected patients with metastatic cancer (non small cell lung; pancreatic; biliary; and melanoma) and their families facing the end of life.

(Plinius) 7/1/2010-6/30/2011 0.30 calendar
Children's Hospital of Philadelphia $24,989

Screening of ROP

Industry Sponsored Clinical Trials

Industry sponsored research.

Aggregated Effort 1.56 Cal Mos.

Duke University lists aggregated effort assigned to the following eligible industry-sponsored clinical trial projects. Each of these individual projects has a varying need of effort depending on the type of activity currently in progress: protocol development, start-up, patient recruitment, enrollment, follow-up, monitoring, data analysis, publication, and closeout. Faculty determine each project's need and adjust their effort between projects within the total aggregated effort assigned to the clinical projects. Effort is reviewed and confirmed by the department based on the activity of each project.

Clinton Pharmaceuticals Corporation (Chopin) 10/1/10 – 9/30/13
$195,971

Economic Parameters in Early Detection of CHI
Industry sponsored research.
Role: Investigator

Gross Phamaceuticals, Inc. (Poe/Chopin) 2/25/2010-8/31/2017
$1,110,469

Economic Analysis Patients vs. Doctors
Role: Investigator
Aggregated Effort Active Only Example

**Baptist Contract Substudy (Pope/Chopin)**  
1/14/2008-4/1/2017  
$752,073  
*TECOS*  
*Economic Analysis of Placebo in Patients with Type 2 Diabetes.*

**Cellini Inc. (Chopin)**  
9/1/2007-11/30/2011  
$718,827  
*EQOL ACEND Sub-Study*  
*Economic Evaluation and Survey Sub-Study Role: Investigator*

**Racine Inc. (Raleigh)**  
12/18/2009-12/31/2011  
$554,500  
*BF ACTION*  
Anemia and its relation to health status, cardiopulmonary fitness and clinical outcomes in the HF-ACTION study. Role: Investigator

Approved:  
SPOC Initials here 5/23/13  
Approved by ORA/Initials here SPS # here 6/13/13
Concurrent Effort Active Only Example

Alcott, Christian

**ACTIVE**

**K24 DA012345** (Alcott)  
NIH  
$137,311

**R01 DA023456** (Marvell)  
NIH  
$222,750

**R01 DA034566** (Alcott)  
NIH  
$150,000  (0.55 concurrent w/K24)

Given that smoking is the single largest preventable cause of death and disease, understanding more about the relationship between ADHD and smoking/nicotine dependence therefore has the potential to prevent or treat a major public health and mental health problem.

**R01 DA056788** (Alcott)  
NIH  
$249,890  (0.55 concurrent w/K24)

Comorbid ADHD

The overarching goal of the present application is to use neuroimaging, neuropharmacological and molecular genetic techniques to study the neurobiological basis of abstinence-induced deficits in response inhibition in ADHD and non-ADHD smokers.

**R03 DA034566** (Alcott)  
NIH  
$150,000  (0.55 concurrent w/K24)

Smoking abstinence

The proposed project will examine the genetic basis of individual differences in inhibitory control (IC) and how these factors interact to increase severity of abstinence-induced smoking withdrawal and subsequent smoking reinforcement.

<table>
<thead>
<tr>
<th>(Alcott)</th>
<th>10/26/09-09/30/11</th>
<th>0.12 calendar months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hilshire Pharmaceuticals</td>
<td>$280,312</td>
<td></td>
</tr>
</tbody>
</table>

Glucose allergy

<table>
<thead>
<tr>
<th>(Alcott)</th>
<th>03/01/10-02/28/12</th>
<th>0.24 calendar months</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Point Pharmaceutical Co.</td>
<td>$392,900</td>
<td></td>
</tr>
</tbody>
</table>

Attention-deficit/Hyperactivity Disorder

This is a Phase II clinical trial as adjunctive therapy in the treatment of adult ADHD.

<table>
<thead>
<tr>
<th>(Alcott)</th>
<th>02/02/11-12/31/11</th>
<th>0.12 calendar months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somerset Pharmaceuticals L.P.</td>
<td>$109,805</td>
<td></td>
</tr>
</tbody>
</table>

Children with ADHD

Double-Blind Efficacy and Safety Study of Children with Attention Deficit Hyperactivity Disorder with the Study Specifics set forth on Schedule A ("Study")

**R01 DA045678** (Marlowe)  
NIH  
$150,000  (Concurrent w/K24)

Elucidating links

A clearer understanding of the developmental relationship between these symptom domains (HI, IN, CD) and substance use has the potential to elucidate the potential etiology of smoking and problem drinking as well as inform treatment and prevention approaches in both clinical groups and in the general population.

*1.2 cal months requested concurrent with the K24 pending sponsor approval
Concurrent Effort Active Only Example

(Alcott) 07/10/07-06/30/11* 0.12 calendar months
Hobitt Pharmaceuticals $213,480
Smoking Cessation
*Extension pending sponsor approval.

Approved by SPOC Initials here: 4.11.13
Approved by ORA/Initials here SPS # here 6/3/13
William Blake, Ph.D.

Dr. Blake holds a dual appointment at Duke University and the Durham VA (8/8).

**DUKE**

**Active**

**R01 CA081234** (Blake) 04/01/06-02/29/12 0.91 calendar months

NIH $126,716

**Anxiety**

The major goal in this study will potentially lead to benefits in multiple areas. First, the results may serve to inform development of smoking cessation strategies by identifying mechanisms of *ad lib* smoking in a real world setting. Second, this study should significantly advance knowledge about the effects of smoking relapse in smokers with PTSD. Finally, by evaluating possible mechanisms that may be specific to or amplified in a psychiatric patient sample, we may gain a more complete understanding of the psychopathological mechanisms in psychiatric smokers.

**K24 DA012345** (Blake) 05/01/08-04/30/13 6.96 calendar months

NIH $152,777

**Smoking Cessation**

The goal of our research program is to inform the development of smoking cessation strategies in PTSD smokers by identifying mechanisms of smoking that may be present in this group.

**R21 CA123456** (Bronte) 05/08/09-04/30/12 0.77 calendar months

NIH $109,999

**Nicotine Administration**

The goal of this project is to investigate whether supplemental nicotine administration will improve quit rates among PTSD smokers.

**R01 MH023456** (Blake) 08/18/09-05/31/14 2.76 calendar months

NIH $422,829

**Hostility**

The project goals are to examine: (1) hostility in a younger sample of individuals with and without PTSD using state of the art electronic diaries; (2) the independent relationship between PTSD and biomarkers of cardiovascular and metabolic disease; and (3) the contribution of hostility and co-morbid major depressive disorder to the relationship between PTSD and biomarkers of cardiovascular and metabolic disease.

**R01 MH066777** (Manzoni) 09/01/02-04/30/15 0.6 calendar months

NIH $359,988

**Posttraumatic Stress Disorder**

The goal of the project is to examine differences in autobiographical memory of the posttraumatic stress disorder versus individual with trauma exposure and no posttraumatic stress disorder.

**VA**

**Active**

**Merit Review** (Blake) 05/01/08-04/30/12 3 calendar months

Department of Veterans Affairs $150,000 annually

**Nicotine**

The goal of this project is to evaluate the effectiveness of nicotine replacement therapy begun prior to the quit date in smokers with PTSD.

**Merit Review** (Blake) 05/01/09-04/30/12 3 calendar months

Department of Veterans Affairs $280,000 annually

**Identifying Rehabilitation**

The goal of this project is to ascertain risk and protective factors empirically related to violent behavior among veterans returning from service in Afghanistan and Iraq.
VA Appointment Active Only Example

**Merit Review** (Browning)  06/01/06-05/31/11   0.6 calendar months
Department of Veterans Affairs  $150,200 annually
PTSD
The goal of this Merit Review is to investigate how PTSD, anger dysregulation, and cognitive factors are associated with partner violence perpetration among combat veterans.

**Merit Review** (Berkeley)  04/01/11-03/31/14   1.2 calendar months
Department of Veterans Affairs  $199,400 annually
Improving smoking cessation
The goal of this Merit Review is to investigate how PTSD and sleep effect smoking cessation attempts among veterans.

**Merit Review** (Maugham)  05/01/10-04/30/14   0.8 calendar months
Department of Veterans Affairs  $224,000 annually
OEF/OIF Veterans
The goal of this Merit Review is to investigate the effectiveness of internet based smoking cessation treatment for veterans.

Approved by SPOC Initials here:  3.21.12
Approved by ORA/Initials here SPS # here 3/28/12